Recent investigations have converged on the convergence of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GCGR activators are commonly employed for managing type 2 diabetes mellitus, their unexpected consequences on reward circuits, specifically governed by dopaminergic pathways, are gai… Read More